Delivery Order SPE2DB24D1034-SPE2DB25FWEP0
- Not listed
- The Defense Logistics Agency awarded a $14,034.53 delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $17,178.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60 count) on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $10,308.12 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with a completion date of July 22, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a relatively small transaction within the company's extensive federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $11,649.50 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct fulfillment order under AmerisourceBergen's existing contract vehicle with the DLA. The work will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,965.60 to AmerisourceBergen Drug Corp for Eliquis 5 mg tablets (60-count supply) on July 21, 2025, with completion targeted for July 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and reflects standard pharmaceutical procurement through the federal medical supply chain. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,514.22 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This competitive award, issued on a firm fixed-price basis with no set-aside designation, represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $7,290.13 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on April 21, 2025, with completion targeted for April 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a direct delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The pharmaceutical will be sourced from the...
- The Defense Logistics Agency awarded a delivery order valued at $17,149.40 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) with an ultimate completion date of August 26, 2025. This firm fixed price delivery order, awarded on August 25, 2025, represents a non-competitive set-aside award executed through open competition. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order valued at $19,111.33 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). This contract, executed on July 29, 2025, with an ultimate completion date of July 30, 2025, utilizes firm fixed-price pricing and was competitively awarded without any set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at approximately $71,000 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on March 10, 2025, with completion scheduled for March 11, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The pharmaceutical distributor, headquartered in Conshohocken,...
- SPE2DB24D1034Indefinite Delivery Contract
- SPE2DB24D1034-SPE2DB25FWEP0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $34,772.20 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order falls under AmerisourceBergen's existing $999,999,999.00 indefinite delivery vehicle with the DLA Troop Support Medical (designated SPE2DX), which runs through December 2026 and provides comprehensive pharmaceutical support for military healthcare programs globally. AmerisourceBergen's federal contract portfolio demonstrates extensive experience supplying a broad range of pharmaceutical products, medical devices, and specialized healthcare commodities to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's consistent award of competitively bid, non-set-aside contracts reflects its established capability to meet federal procurement requirements across multiple therapeutic domains and order values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.8k | 7/22/25 |